Analysis of cellular and soluble profiles in QuantiFERON nonconverters, converters, and reverters in the Gambia. by Medawar, Lydia et al.
LSHTM Research Online
Medawar, Lydia; Tukiman, Hatimi Mohd; Mbayo, Georgetta; Donkor, Simon; Owolabi, Olumuyiwa;
Sutherland, Jayne S; (2019) Analysis of cellular and soluble profiles in QuantiFERON nonconverters,
converters, and reverters in the Gambia. Immunity, inflammation and disease. ISSN 2050-4527 DOI:
https://doi.org/10.1002/iid3.269
Downloaded from: http://researchonline.lshtm.ac.uk/4654177/
DOI: https://doi.org/10.1002/iid3.269
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
© 2019 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Immun Inflamm Dis. 2019;1–11. wileyonlinelibrary.com/journal/iid3 | 1
Received: 30 April 2019 | Revised: 22 July 2019 | Accepted: 30 July 2019
DOI: 10.1002/iid3.269
OR IG INAL RE S EARCH
Analysis of cellular and soluble profiles in QuantiFERON
nonconverters, converters, and reverters in the Gambia
Lydia Medawar1,2 | Hatimi Mohd Tukiman3 | Georgetta Mbayo1 | Simon Donkor1 |
Olumuyiwa Owolabi1 | Jayne S. Sutherland1
1Vaccines and Immunity Theme, MRC
Unit The Gambia at London School of
Hygiene and Tropical Medicine, Fajara,
Gambia
2Department of Biomedical Sciences,
University of Manchester, Manchester,
UK
3Department of Infectious and Tropical
Diseases, London School of Hygiene and
Tropical Medicine, London, UK
Correspondence
Jayne Sutherland, Vaccines and
Immunity Theme, MRC Unit The Gambia
at London School of Hygiene and Tropical
Medicine, Atlantic Rd, Fajara, The
Gambia.
Email: jsutherland@mrc.gm
Abstract
Background: Tuberculosis (TB) is the leading cause of death from a single
infectious agent worldwide. The immune system is capable of clearing the
pathogen before establishment of latent infection but the mechanisms for this
are not yet understood.
Methods: This study analysed highly exposed household contacts (HHC) of TB
index cases who were categorised according to QuantiFERON (QFT) results at
recruitment and 6 months. Seventeen (17) QFT nonconverters, 14 QFT
converters, 18 QFT reverters and 18 latent TB infection (LTBI) were analysed.
Supernatants generated following QFT stimulation at both time‐points were
analysed using a 64‐plex cytokine array. Flow cytometry was performed on QFT
converters and nonconverters at baseline only.
Results: Interleukin‐2 (IL‐2), IL‐5, IL‐13, APRIL, IL‐17A, IP‐10, MIP‐1ß, sIL‐6rb,
OPN, and sTNFR2 were all significantly higher in the QFT converters compared
with nonconverters at baseline. Levels of interferon‐α2 (IFN‐α2) and IL‐2 were
significantly lower in QFT reverters compared with nonconverters at baseline.
Analysis of Ag‐specific IL‐2 levels resulted in an area under the curve (AUC) of
0.93 (95% confidence interval [CI], 0.84‐1.00) for QFT converters compared to
nonconverters and an AUC of 0.80 (0.65‐0.95) for QFT reverters compared with
LTBI. Purified protein derivative (PPD)‐specific CD4+CD26+ IFN‐γ+cells were
significantly increased (P= .0007) in QFT nonconverters compared with QFT
converters at baseline.
Conclusions: Our results provide insight into the underlying mechanisms of
resistance to sustained Mycobacterium tuberculosis infection.
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1 | INTRODUCTION
Tuberculosis (TB) is the leading cause of death from a
single infectious agent, and the ninth leading cause of death
worldwide. In 2017, TB caused an estimated 1.6 million
deaths, with 10.0 million new cases.1 Despite its prevalence
there is a major gap in knowledge as to what constitutes
natural protective immunity to TB, which precludes
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development of optimal vaccines. Whilst a vaccine is
available (Bacillus Calmette–Guérin [BCG]), protection is
highly variable and depends on age, setting and study
quality.2,3 Several pipeline vaccines are in development with
the most successful, M72/AS01E, recently shown to provide
50% protection against adult pTB.4 However, the mechan-
ism underlying this is unclear.5 Analysis of individuals who
appear to “resist” development of latent TB infection (LTBI)
and those who can actively clear infection would provide
novel insights into natural protective immunity to Mtb.6
Evidence for natural protection from Mtb infection
comes from the consistent finding that a proportion of
highly Mycobacterium tuberculosis (Mtb)‐exposed indivi-
duals do not acquire Mtb infection.7,8 This is best illustrated
by the Lübeck disaster where ~20% of infants vaccinated
with Mtb‐contaminated BCG did not get infected.9 In
addition, studies of sailors in long‐term confinement with a
TB patient showed a surprisingly low level of infection
suggesting they were naturally resistant to Mtb infection.10
Importantly, longitudinal studies of these “resisters” con-
firm a much lower rate of progression to TB disease than
those with LTBI.11 However, there are limitations in our
interpretation of these cohorts based solely on IFN‐γ
production with a recent paper highlighting potential
IFN‐γ‐independent immune markers of Mycobacterium
tuberculosis exposure.12 Thus, an expanded definition of
the host response to Mtb exposure is needed.12
Sterilizing immunity is rarely achieved in animal and
humanMtb infections. However, TST reversion was evident
in 22% of guinea pigs exposed for up to 5 months to TB
patients and this correlated with clearance of an established
infection.13 Tuberculin skin test (TST) and QuantiFERON
(QFT; a commercially available interferon (IFN)‐gamma
release assay IGRA test) reversion are also evident in
humans.14,15 In a recent study BCG revaccination of
adolescents had 45.4% efficacy against sustained Mtb
infection. It was proposed that this reversion was due to a
combination of innate and adaptive responses that gener-
ated enhanced control or, critically, clearance of bacteria15
but the underlying mechanisms are yet to be defined.
The cocktail of cytokines and chemokines produced by
the body following Mtb exposure are crucial to the outcome
of infection. IFN‐γ is a classical proinflammatory cytokine
which is first induced by phagocytes in the innate immune
system due to recognition of Mtb with pattern recognition
receptors (PRRs) and subsequently by activated T cells.16 It
has been used to define infection status in exposed
household contacts following stimulation with Mtb‐specific
antigens, as seen with the QFT assay.14 However, it is the
balance between pro‐ and anti‐inflammatory mediators
together that determines the outcome of the immune
response to Mtb. Therefore this study aimed to analyse
individuals who remained uninfected despite high exposure
and those who cleared an active infection before establish-
ment of sustained (ie, latent) Mtb infection to define the
underlying immune mediators.
2 | METHODS
2.1 | Subject recruitment
This study was nested within a longitudinal cohort study
of consecutively recruited household contacts at MRCG.
Following identification of GeneXpert positive index TB
patients, their exposed household contacts were assessed
for signs and symptoms of TB. For asymptomatic
individuals, the most highly exposed (ie, sleeping in the
same room as the index TB patient) were included in this
study after written informed consent. QFT‐GIT was
performed at baseline and 6 months to determine Mtb
infection status: QFT nonconverters = two negative read-
ings; LTBI = 2 positive readings, QFT converters = nega-
tive at baseline and positive at 6 months and QFT
reverters = positive at baseline and negative at 6 months.
To avoid the “grey zone,” negative QFT was defined as
less than or equal to 0.2 IU/mL and a positive QFT was
defined as greater than or equal to 0.7 IU/mL. QFT
supernatants from NIL, Mitogen and antigen tubes were
stored and used for subsequent multiplex cytokine assays.
For flow cytometry analysis, a heparinised venous blood
sample was taken for PBMC separation and storage at
baseline. This study was approved by the MRCG and
Gambia government joint ethics committee.
2.2 | Multiplex cytokine assays
Multiplex human cytokine assays were performed using
Bio‐Plex Pro Human Cytokine 27‐plex kit (IL‐1β, IL‐1ra,
IL‐2, IL‐4, IL‐5, IL‐6, IL‐7, IL‐8, IL‐9, IL‐10, IL‐12p70, IL‐
13, IL‐15, IL‐17, basic FGF, eotaxin, G‐CSF, GM‐CSF,
IFN‐γ, IP‐10, MCP‐1, MIP‐1α, MIP‐1β, PDGF‐BB,
RANTES, TNF‐α, VEGF) and Bio‐plex Pro 37‐plex
Human Inflammation Panel I (APRIL/TNFSF13, BAFF/
TNFSF13B, sCD30/TNFRSF8, sCD163, Chitinase‐3‐like
1, gp130/sIL‐6Rβ, IFN‐α2, IFN‐β, IFN‐γ, IL‐2, sIL‐6Rα,
IL‐8, IL‐10, IL‐11, IL‐12(p40), IL‐12(p70), IL‐19, IL‐20, IL‐
22, IL‐26, IL‐27(p28), IL‐28A/IFN‐λ2, IL‐29/IFN‐λ1, IL‐
32, IL‐34, IL‐35, LIGHT/TNFSF14, MMP‐1, MMP‐2,
MMP‐3, Osteocalcin, Osteopontin, Pentraxin‐3, sTNF‐
R1, sTNF‐R2, TSLP, TWEAK/TNFSF12 (BioRad, Bel-
gium) according to the manufacturer’s instructions.
Briefly, lyophilised standards and controls were recon-
stituted in standard diluent. Coupled beads were diluted
in assay buffer and 50 µL added to each well of a flat‐
bottomed 96‐well plate. Fifty microliters of either
standards, samples, blanks or controls was added to each
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well followed by an hour‐long incubation on an
automated Microplate shaker at room temperature
(RT). The plate was then washed three times in wash
buffer and 25 µL of diluted detection antibodies were
added to each well. Plates were wrapped in foil and
shaken for 30minutes at 400gmax. Plates were then
washed three times and 50 µL of diluted SA‐PE was
added to each well. The plate was wrapped in foil and
shaken for 10minutes at 400gmax. The plate was then
washed three times, beads resuspended in 125 µL assay
buffer, shaken for 30 seconds at 400gmax and read using a
Magpix multiplex plate reader (BioRad, Belgium).
2.3 | Flow cytometry
2.3.1 | Antigen stimulation
Cryopreserved PBMC from QFT converters and non-
converters at baseline were thawed and rested for 6 hours
at 37°C, 5% CO2 in RPMI + 10% FCS (RP10) + 0.1%
Benzonase. Following resting cells were counted and 0.5
million viable cells stimulated with RP10 only (NIL) or
PMA (cell stimulation cocktail, eBioscience). The follow-
ing day PMA‐stimulated cells were restimulated over-
night with specific antigens: ESAT‐6/CFP‐10 fusion
protein (EC; kindly provided by Prof. T.H.M. Ottenhoff),
PPD (both at a final concentration of 10 μg/mL) or RP10.
2.3.2 | Antibody staining
Following incubation, cells were washed in 1mL
fluorescence‐activated cell sorting (FACS) buffer (PBS/
FCS/Az) at 600gmax, supernatant removed and incubated
with live‐dead cascade yellow (Invitrogen, UK) for
10 minutes, RT. After washing, cells were stained with
a surface cocktail consisting of anti‐CD3‐BV421, anti‐
CD8‐eFluor 780, and anti‐CD26‐FITC (Biolegend, UK)
and incubated for 15 minutes at 4°C. Following washing,
cells were fixed (Fix/Perm buffer, BD) for 15 minutes at
4°C, permeabilised for 20minutes at RT in the dark
(Perm/Wash buffer, BD) and incubated with intracellular
cytokines: anti‐IL‐17‐PE, anti‐TNF‐α‐PE‐Cy7, and anti‐
IFN‐γ‐Alexa Fluor 700 (all from Becton Dickinson) for
30 minutes at RT in the dark. After a final wash, cells
were resuspended in 300 μL of FACS buffer and acquired
using a BD Fortessa.
2.4 | Data analysis
Multiplex assay results were exported from Bio‐plex
Manager Software version 6.1 (Bio‐Rad, Belgium) to
Microsoft Excel. Cytokine concentrations outside the
measurable range, as indicated by the Bio‐plex software,
were set at either half the bottom standard concentration
or double the top standard concentration, for those out of
range below and out of range above, respectively.
Cytokine responses of the unstimulated (NIL) samples
were subtracted from the Ag and Mit data to generate Ag‐
NIL and Mit‐NIL final results. Data were analysed with
GraphPad Prism 7 (Software MacKiev). Mann‐Whitney
or the Kruskal‐Wallis test (with Dunn’s posttest compar-
ison) was used to determine significant differences
between the groups. Only P≤ .035 were considered
statistically significant, to account for False Discovery
Rate (FDR). For flow cytometry analysis, raw FCS files
were analysed using FlowJo v.10.4.2 (Becton Dickinson)
with combination gates for Boolean cytokine analysis.
Results for PMA‐only stimulated samples were sub-
tracted from PMA+EC and PMA+ PPD stimulated
samples to generate EC and PPD specific responses.
Differential cytokine responses between converters and
nonconverters was analysed using PESTLE and SPICE.17
3 | RESULTS
3.1 | Characteristics of study
participants
Seventeen (17) QFT nonconverters, 14 QFT converters, 18
QFT reverters, and 18 LTBI were included in the final
multiplex cytokine analyses (Table 1). There were no
significant differences in age between the groups with the
median [interquartile range (IQR)] of 22 [18 to 28], 30 [25
to 60], 23 [19 to 35] and 31 [27 to 44], respectively.
However, the LTBI group had a lower % of males
compared with the other three groups (22% compared
with 53% for TBR, 50% for QFTC and 39% for QFTR). The
median [IQR] QFT Ag‐NIL IFN‐γ levels were 0[0‐0] and
0[0‐0.1] at baseline and 6 months for the QFT nonconverter
group; 3.2 [0.6 to 10] and 5.6 [2 to 10] IU/mL at 0 and 6
months, respectively, for the LTBI group; 0[0‐0.1] and 1.6
[0.9 to 10] at 0 and 6 months, respectively, for the QFT
converter group and 6.3 [2.5 to 10] and 0[0‐0.3] at 0 and 6
months, respectively, for the QFT reverter group (Table 1).
Fifty‐nine percent of nonconverters and 71% of converters
were BCG vaccinated (P= .70; relative risk 1.38). For flow
cytometry analysis a subset of 10 QFT converters and 10
nonconverters were analysed. There were no differences in
age or sex between the groups (Table 1).
3.2 | Inflammatory profiles in QFT
converters versus nonconverters
Analysis of Ag‐NIL cytokine levels at baseline showed
that QFT converters had significantly higher levels of
IL‐2 (P< .0001), IL‐5 (P= 0.0245), IL‐13 (P= .0003),
APRIL (P= .0218), IL‐17A (P= .0043), IP‐10 (P= .0073),
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MIP‐1β (P= .0225), sIL‐6RB (P= .0261), Osteopontin
(OPN) (P= .0079), and sTNFR2 (P= .0218) than the
nonconverter group (Figure 1). Interestingly, the only
analytes that showed a difference in unstimulated
samples were CHI3L1 and IL‐9 which were both
significantly higher in the converters compared with
nonconverters at baseline (P= .0209 and P= .0278,
respectively; data not shown). No differences in mitogen
responses were seen between the groups at baseline (data
not shown).
TABLE 1 Study participants
Multiplex assay Nonconverter Converter Reverter LTBI
Multiplex assay, (n) 17 14 18 18
Age, median [IQR] 22 [18‐28] 30 [25‐60] 23 [19‐35] 31 [27‐44]
Males, n (%) 9 (53) 7 (50) 7 (39) 4 (22)
Baseline QFT, median [IQR] 0 [0‐0] 0 [0‐0.1] 6.3 [2.5‐10] 3.2 [0.6‐10]
6 month QFT, median [IQR] 0 [0‐0.1] 1.6 [0.9‐10] 0 [0‐0.3] 5.6 [2‐10]
BCG vaccinated n (%) 10 (59) 10 (71) 7 (39) 13 (72)
Flow cytometry, (n) 10 10 n/a n/a
Age, median [IQR] 27 [21‐35] 32 [24‐63] n/a n/a
Males, n (%) 6 (60) 8 (80) n/a n/a
Abbreviations: LTBI, latent tuberculosis infection; IQR, interquartile range; QFT, QuantiFERON.
FIGURE 1 Analysis of Ag‐NIL supernatants in QFT converters (C) and nonconverters (NC). Whole blood was stimulated overnight
with QFT Ag or NIL tubes. Luminex analysis was performed. Background was subtracted (Ag‐NIL) and data were analysed using the
Mann‐Whitney U test. Line indicates median. P values are indicated. IL, interleukin; QFT, QuantiFERON
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3.3 | Inflammatory profiles in LTBI vs
QFT reverters
Individuals with sustained infection (LTBI) vs QFT
reverters were only analysed using the 37‐plex inflamma-
tion panel kit. In Ag‐NIL samples, the concentration of
IFN‐γ, IL‐2, and IL‐22 were all significantly lower by 6
months compared with baseline in QFT reverters
(P= .0002; P= .0039 and P= .0039, respectively) (data
not shown). There was also a significantly lower level of
IFN‐α2 and IL‐2 in QFT reverters compared with LTBI at
baseline despite no difference in their QFT (IFN‐γ) levels
(P= .03 and P= .001, respectively; Figure 2). Interest-
ingly there were no differences between LTBI and active
TB at baseline (data not shown). At the 6‐month time‐
point (ie, post‐reversion), LTBI had significantly higher
levels of IFN‐γ (P= .0002), IL‐2 (P< .0001), MMP‐3
(P= .0186) and IL‐22 (P= .0022) compared with QFT
reverters and significantly higher levels compared with
QFT nonconverters at baseline (P< .0001, P= .0007,
P= .0217 and P= .0334, respectively; Figure 2). QFT
reverters at 6 months had comparable levels of all
analytes to QFT nonconverters supporting active clear-
ance of the Mtb infection (Figure 2).
3.4 | Receiver operated curve analysis
Receiver operated curve (ROC) analysis was performed
for QFT nonconverters compared with converters (Figure
3A and 3B) and for QFT reverters compared with LTBI
(Figure 3C and 3D). For QFT converters and nonconver-
ters, analysis of IL‐2 levels in Ag‐NIL supernatants at
baseline gave an area under the curve (AUC) of 0.93 (95%
confidence interval [CI], 0.84‐1.00) with a sensitivity of 90
(68‐99) % and specificity of 85 (62‐97) % at a cut‐off of
10.5 pg/mL (Figure 3A). The next best analyte for
discrimination between QFT converters and nonconver-
ters was IL‐13 with an AUC of 0.82 (95% CI, 0.69‐0.96)
(Figure 3B). For LTBI vs QFT reverters, analysis of IL‐2
levels in Ag‐NIL supernatants at baseline resulted in an
AUC of 0.80 (95% CI, 0.65‐0.95), sensitivity of 61 (36‐83)
% and specificity of 94 (79‐100) % (Figure 3C) while IFN‐γ
alone resulted in an AUC of 0.76 (95% CI, 0.6‐0.92)
(Figure 3D).
3.5 | Cellular immune profiles in QFT
nonconverters
Total CD4+, CD8+, and Th17 responses to Mtb antigens in
QFT converters and nonconverters were analysed by flow
cytometry to determine the role of adaptive immunity in
Gambian QFT nonconverters. IFN‐γ, tumor necrosis factor
(TNF‐α), and IL‐17 production was analysed using Boolean
gating strategies and combinations of cytokines assessed for
total CD4+, CD8+, and Th17 cells (Figure 4). When total
CD4+ and CD8+ T cells were analysed, no difference in
mono‐ or polyfunctional cytokine levels was seen for any
stimulation (Figure 5A, pies). CD8+ T cells were pre-
dominantly IFN‐γ+TNF‐α+ (light blue) with a small
proportion producing IL‐17 either alone (dark green) or in
conjunction with TNF‐α (light green) (Figure 5A CD8+
pies). CD4+ T cells were predominantly TNF‐α+mono‐
functional (purple) followed by IFN‐γ+TNF‐α+ (light
blue) and IL‐17+TNF‐α+ (light green). Very few were
IFN‐γ monofunctional (dark blue) in contrast to CD8+ T
cells. The unstimulated (NIL) samples showed a signifi-
cantly higher proportion of CD4+ IFN‐γ+TNF‐α+ IL‐17‐
cells in QFT nonconverters compared with QFT converters
at baseline (P= .006; Figure 5B).
FIGURE 2 Analysis of Ag‐NIL supernatants in QFT Reverters
(QFTR) vs LTBI. Whole blood was stimulated overnight with QFT
Ag or NIL tubes. Luminex analysis was performed. Background
was subtracted (Ag‐NIL) and data were analysed using the
Mann‐Whitney U test. Line indicates median. P values are
indicated. IL, interleukin; LTBI, latent TB infection; NC,
nonconverters; QFT, QuantiFERON
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We also analysed cytokine production from CD26+
CD4+ cells (Figure 6A). CD4+ CD26+ cells were highly
polyfunctional with up to 2% of cells producing TNF‐α,
IFN‐γ, and IL‐17 simultaneously following both EC and
PPD stimulation (red pie section [only PPD shown]).
Following PPD stimulation, QFT nonconverters had a
significantly higher proportion of CD4 + CD26 + IFN‐
γ+mono‐functional cells compared with QFT converters
at baseline (P= .007; dark green pie; Figure 6B).
4 | DISCUSSION
Analysis of individuals who are highly exposed to Mtb
but never become latently infected and those who are
able to actively clear the infection before development of
sustained (latent) Mtb infection hold the key to under-
standing the mechanisms of early protection to Mtb. The
aim of this study was to analyse cellular and soluble
markers in highly exposed individuals who remain
uninfected (QFT nonconverters) compared with those
who become latently infected (QFT converters). We
found several inflammatory mediators that were differ-
entially expressed in QFT nonconverters compared with
converters and QFT reverters compared with LTBI. In
addition, QFT nonconverters had significantly higher
levels of Mtb‐specific CD4 + IFN‐γ+TNF‐α+ and Th1‐
like CD26 + CD4 + cells (ie, IFN‐γ producing only18) cells
at baseline compared with QFT converters.
In QFT converters, Mtb‐antigen‐specific levels of IL‐2
were significantly increased at baseline compared with
nonconverters. In previous studies IL‐2 has been shown
to enhance diagnosis of LTBI, particularly in those with
borderline QFT results.19 In addition, IL‐2 levels are
generally higher in LTBI compared with active TB
patients.20 Our results showing elevation of IL‐2 before
IFN‐γ conversion by QFT suggests IL‐2 is a likely marker
of early infection leading to subsequent conversion. We
also found that IL‐2 was significantly lower in QFT
reverters at recruitment ie before reversion suggesting it
is also decreased when the pathogen is being actively
cleared and could be used as a biomarker for sterilizing
TB. Importantly, at the follow‐up time‐point, levels of all
analytes in the QFT reverter group were indistinguish-
able from the QFT nonconverters at baseline further
suggesting they had actively cleared the infection. One
limitation of our study was the lack of a third time‐point
to assess the stability of the phenotypes analysed and this
should be performed in future studies.
The second‐best marker for discrimination of QFT
converters and nonconverters was IL‐13, which was also
significantly higher at baseline in the QFT converters.
(A) (B)
(C) (D)
FIGURE 3 Receiver operated curve
(ROC) analysis of Ag‐NIL supernatants.
Nonconverters vs converters (A, IL‐2; B,
IL‐13). QFT reverters vs LTBI (C, IL‐2; D,
IFN‐γ). Whole blood was stimulated
overnight with QFT Ag or NIL tubes.
Luminex analysis was performed and
background was subtracted (Ag‐NIL).
Data were analysed using a ROC. Area
under the curve (AUC) with 95%
confidence intervals are indicated. IL,
interleukin; IFN‐γ, interferon‐γ; LTBI,
latent TB infection; QFT, QuantiFERON
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IL‐13 is a Th2 cytokine closely related to IL‐4. It is
thought that Th2 cytokines such as IL‐13 can cause
inappropriate activation of macrophages and thus,
undermine the Th1 response suitable for an intracellular
pathogen like Mtb.21 We also found increased levels of
IL‐17A, IP‐10 and MIP1β in converters compared with
nonconverters. IL‐17A is associated with Th17 responses
with a previous study from our laboratory showing
contrasting findings (ie, increased IL‐17A in TBR).22 This
difference may be due to the techniques used to classify
the groups. In the initial study, an in‐house enzyme‐
linked immunosorbent assay (ELISA) was used with only
ESAT‐6/CFP‐10 peptides, whereas the present study used
commercial QFT Gold‐In Tube, which includes addi-
tional peptides of TB7.7. The previous study also
shohwed reduction in cellular IL‐17 production in
nonconverters compared with converters following mito-
gen stimulation. We thus wanted to test whether this was
also true for antigen‐specific responses. Interestingly we
found no difference in the total proportion of Th17 cells,
nor in the antigen‐specific production of IL‐17. However,
we did see a significantly higher proportion of PPD‐
specific Th‐1 like Th17 (CD26 + CD4 + ) cells in QFT
nonconverters. QFT nonconverters also had significantly
higher basal levels of CD4 + IFN‐γ+TNF‐α+ cells. It is
interesting to note that cellular IFN‐γ production appears
to be elevated in QFT nonconverters despite a lack of
QFT positivity, which is likely due to the antigens used
for stimulation. QFT includes peptides to ESAT‐6 and
CFP‐10, which we saw no difference in response to, but
(A)
(B)
(D)(C)
FIGURE 4 Gating strategy for analysis of polyfunctional CD4+ and CD8+ T cells. A, Lymphocytes were gated using FSC and SSC. B,
From this, CD4+ and CD8+ T cells were gated using CD3 vs CD8 (CD3+ CD8+, CD8+ T cells; CD3+ CD8−, CD4+ T cells). Both CD4+ and
CD8+ T cells were then analysed using Boolean gating for IL‐17, IFN‐γ (C) and TNF‐α (D). IL, interleukin; IFN‐γ, interferon‐γ; LTBI, latent
TB infection; QFT, QuantiFERON
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not to any broader Mtb antigens. The differential
responses in our flow cytometry analysis were seen with
PPD suggesting there could be some priming due to BCG.
This should be tested in future studies. It was also a
limitation that we did not analyse QFT reverters and did
not include IL‐2 in our panel since this cytokine
was discriminatory between the nonconverters and
converters. Again, this should be addressed in future
studies. It is interesting to note that the majority of
differences we saw were in the adaptive immune system,
which supports recent findings in a Ugandan cohort of
Mtb “resisters.”12 However, another recent study from
Indonesia showed stronger innate responses to hetero-
logous stimuli in IGRA nonconverters.23 It’s likely that
(A)
(B)
FIGURE 5 Polyfunctional T cell responses in QFT converters compared with nonconverters. A, Pie graphs indicating polyfunctionality
of CD4+ T cells (left) and CD8+ T cells (right) responses to all stimulations used (NIL, EC‐PMA, PPD‐PMA, PMA alone). B, Graphical
analysis of polyfunctional responses to NIL (unstimulated) samples in QFT converters (blue) compared with nonconverters (red). Data were
analysed using the Mann‐Whitney U test. Colours correspond with pie section. QFT, QuantiFERON
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(A)
(B)
FIGURE 6 Analysis of Th17 polyfunctionality from QFT converters and nonconverters. A, Gating strategy for analysis of Th17 cells.
CD26+ CD4+ cells were gated followed by Boolean gating of IL‐17+, IFN‐γ+, and TNF‐α+ cells. B, Analysis of IFN‐γ+ IL‐17‐TNF‐α‐
CD26 + CD4+ T cells following PMA+ PPD stimulation (PMA subtracted). Pies on right show all subsets analysed. Data were analysed
using the Mann‐Whitney U test. Line indicates median. IL, interleukin; IFN‐γ, interferon‐γ; LTBI, latent TB infection; NC, nonconverters;
QFT, QuantiFERON
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different host and pathogen genetics will play a role but
the cohort in Indonesia also included children which
may have a bias to innate cell responses. Similarly, this
may explain why we saw no influence of BCG on
prevention of infection in our cohort.
In our study, participants were all HIV‐negative and
those with QFT results in the grey zone were excluded.
Thus, we have tried to control for spontaneous conver-
sion/reversion. However, it is imperative that future
studies include at least one more time‐point to ensure
stability of both phenotypes. The fact that values for all
cytokines reverted to levels seen in our nonconverters at
baseline suggests that our findings are accurate, but
inclusion of a further time‐point together with TST to
exclude any discordant readings, would enable us to have
a robust phenotype, which was outside the scope of the
present study. Indeed, one of the major reasons for
investigating QFT responses in our Gambian cohort is
due to the lack of TST availability in‐country. It would
also be important to assess responses at the site of
infection through bronchoalveolar lavage (BAL)24 or
PET/CT scanning25; neither of which are currently
possible in The Gambia. Finally, it will be important to
determine the cellular source of the soluble markers we
have identified, particularly IL‐2. In addition, caution
must be taken in regard to the definition of infection by
IFN‐γ production alone as described in a recent paper by
Lu et al.11
In conclusion, our results provide biological insight
into the underlying mechanisms of resistance/active
clearance of Mtb infection. Importantly, IL‐2 was shown
to be a marker of both early conversion and early
reversion while Th1‐like Th17 cells are potentially
actively involved in early protective immunity to Mtb.
Further studies should assess these factors in larger,
ethnically diverse cohorts with further follow‐up time‐
points together with assessment of the lung microenvir-
onment.
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